Cantor Fitzgerald Defends Corbus Pharmaceuticals (CRBP) Following Short Report
Tweet Send to a Friend
Cantor Fitzgerald analyst Elemer Piros came out to defend Corbus Pharmaceuticals (NASDAQ: CRBP), which is down 22% after the short ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
